We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · November 30, 2020

Abicipar for Neovascular Age‐Related Macular Degeneration

Ophthalmology: Journal of the AAO


Additional Info

Ophthalmology: Journal of the AAO
Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration
Ophthalmology 2020 Nov 19;[EPub Ahead of Print], RN Khurana, D Kunimoto, YH Yoon, CC Wykoff, A Chang, RK Maturi, H Agostini, E Souied, DR Chow, AJ Lotery, M Ohji, F Bandello, R Belfort, XY Li, J Jiao, G Le, K Kim, W Schmidt, Y Hashad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading